Key summary:

The study found no increased risk of sudden death associated with attention-deficit hyperactivity disorder (ADHD) medications [methylphenidate (Ritalin®), dexamfetamine (Dexedrine®), and atomoxetine (Strattera®)]. An increased risk of suicide was seen in the patients with medication prescription in the study comparing with the general population, but such risk may be contributed by other factors such as common psychiatric co-morbidities e.g. bipolar disorder, depression and anti-social behaviour. Special attention and close monitoring should be given to patients with severe co-morbid conditions, increased risks of cardiovascular events and suicide.